Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Roche’s xCELLigence Cardio Instrument Used to Detect Compound Effects on Beating Frequency of Cardiomyocytes

Published: Friday, February 10, 2012
Last Updated: Friday, February 10, 2012
Bookmark and Share
Scientists at the University Medical Center Utrecht and Bioscience Department of AstraZeneca R&D have tested Roche’s xCELLigence Cardio Instrument.

In an effort to improve preclinical cardiotoxicity assays, reduce drug testing attrition rates, and ensure drug safety, collaborating scientists at the University Medical Center Utrecht in the Netherlands, and Bioscience Department of AstraZeneca R&D, Mölndal, Sweden, have tested Roche’s xCELLigence Cardio Instrument.

Their goal was to determine whether impedance recordings are a useful way to detect compound effects on beating frequency of cardiomyocytes, derived either from human induced pluripotent stem cells (hiPS), or from mouse embryonic stem cells (mESC).

The xCELLigence Cardio Instrument is an impedance sensing instrument capable of reading signals at high sampling rates, making it possible to measure the contraction movements of
cardiomyocytes in contact with sensor microelectrodes.

In this study, the effects of nine compounds were tested on beating frequency (beats per minute, bpm) of hiPS and mESC cardiomyocytes.

The authors reported, “The results of this initial study show that, under the right conditions, the beating frequency of a monolayer of cells can be stably recorded over several days. In addition, the xCELLigence System detects changes in beating frequency and amplitude caused by added reference compounds.”

The authors conclude that xCELLigence Cardio instrument has potential for 96-well-throughput cardiotoxicity screening of the effects of compounds on rhythmic beating patterns of cardiomyocytes.

They underscored the need for continuous improvements in the maturation of available cardiomyocytes and in further validation of the assay on an extended set of reference compounds with known in-vivo effects.

They also indicated that the production of distinct subtypes of ventricular, atrial and nodal cardiomyocytes could open up new areas of screening for arrhythmia and cardiotoxicity.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

First European Laboratory Obtains Accreditation for New Tissue-Typing Method for Stem Cell Transplants
Tests based on next-generation sequencing with Roche’s GS Junior System.
Thursday, February 28, 2013
Birmingham hospital uses Roche automation solution at blood sciences laboratory
Roche’s automated track system is being used at Queen Elizabeth Hospital to streamline processes and improve turnaround times.
Saturday, June 02, 2012
Roche’s xCELLigence Cardio Instrument Used to Study Stem Cell-Derived Cardiomyocytes
Instrument detected beating rhythm and proarrhythmic effects of nine different compounds on a monolayer of cells, providing evidence for the potential of future screening assays.
Monday, February 13, 2012
Roche’s new RTCA Cardio Instrument for Label-Free Functional Cardiomyocyte Toxicity Testing
New medium-throughput cell analyzer utilizes impedance readings to monitor cardiac beating and cellular events in real time.
Wednesday, September 29, 2010
Roche Applied Science Introduces new xCELLigence RTCA MP Instrument
The xCELLigence RTCA MP allows high throughput online-measurement of cell activities without labeling.
Friday, December 05, 2008
454 Sequencing at the Forefront of Bone Marrow and Stem Cell Therapy Research
Roche Genome Sequencer FLX System will create new opportunities for HLA research at the Blood Centre Linz, Austria.
Monday, June 30, 2008
Scientific News
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Zebrafish Reveal Drugs that may Improve Bone Marrow Transplant
Compounds boost stem cell engraftment; could allow more matches for patients with cancer and blood diseases.
New Material Forges the Way for 'Stem Cell Factories'
Researchers have discovered the first fully synthetic substrate with potential to grow billions of stem cells. The researchcould forge the way for the creation of 'stem cell factories' - the mass production of human embryonic (pluripotent) stem cells.
Liver Regrown from Stem Cells
Scientists have repaired a damaged liver in a mouse by transplanting stem cells grown in the laboratory.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
'Google Maps' for the Body
Scientists have revealed research that uses previously top-secret technology to zoom through the human body down to the level of a single cell that could be a game-changer for medicine.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!